Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given…
Read on
Playing fetch or grooming Fido isn’t just good for your precious pooch — it also benefits your brain. Such interactions appear to strengthen brain waves…
Read on
Take the stairs. Tote heavy shopping bags. Walk up that hill. Play tag with a kid or a pet. Weaving these tiny bursts of vigorous…
Read on
So-called crisis pregnancy centers, often created with an anti-abortion agenda, are providing pregnant women some questionable medical advice alongside potentially helpful services, a new study…
Read on
The collected evidence is in, and drinking about eight cups of water per day is, in fact, good for you. So says a University of…
Read on
Premature babies not only face serious and immediate health consequences: New research shows they are also more likely to die early, a risk that persists…
Read on
Certain hormone replacement therapy pills appear to increase the risk of heart disease and serious blood clots in women going through menopause, a new study…
Read on
The rate and number of abortions among U.S. women took a slight dip in 2022 compared to 2021, according to the latest data from the…
Read on
The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of…
Read on
WEDNESDAY, Nov. 27, 2024 — Thanksgiving travel is a must for millions of Americans, but those plans will be complicated for some because they’re traveling…
Read on
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However,…
Read on
It’s common to find a pitcher soaking their elbow in an ice bucket following a baseball game, in an effort to save their arm for…
Read on